M. Maitland

发表

Clinical trials in the era of personalized oncology

M. Maitland, R. Schilsky, 2011, CA: a cancer journal for clinicians.

Cancer pharmacogenomics: strategies and challenges

M. Eileen Dolan, Nancy J. Cox, Mark J. Ratain, 2012, Nature Reviews Genetics.

A Dosing/Cross‐Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension

M. Maitland, M. Ratain, M. Lacouture, 2010, Clinical pharmacology and therapeutics.

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

Michael L Maitland, Walter M Stadler, Mark J Ratain, 2007, Journal of the National Cancer Institute.

Other Paradigms: Better Treatments Are Identified by Better Trials: The Value of Randomized Phase II Studies

Manish R. Sharma, M. Maitland, M. Ratain, 2009, Cancer journal.

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

M. Maitland, M. Ratain, J. Ramírez, 2012, Clinical Cancer Research.

Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.

M. Maitland, T. Conrads, D. Kimble, 2020, Gynecologic oncology.

Polymorphisms of adrenergic receptors and the risk of heart failure.

M. Maitland, M. Gomberg-Maitland, 2003, The New England journal of medicine.

Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.

M. Maitland, S. Ong, Taosheng Chen, 2016, Cancer research.

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Ming-Hui Chen, M. Maitland, G. Bakris, 2012, American heart journal.

Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.

M. Maitland, M. Ratain, G. Bakris, 2013, The oncologist.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

M. Maitland, M. Ratain, R. Kurzrock, 2018, British Journal of Cancer.

Why RECIST works and why it should stay--reply to counterpoint.

Manish R. Sharma, M. Maitland, M. Ratain, 2012, Cancer research.

More sound cancer therapy biomarker development with active noise control.

M. Maitland, 2013, The oncologist.

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

M. Maitland, A. Tolcher, S. Ou, 2016, Journal of Hematology & Oncology.

Vascular endothelial growth factor pathway.

Russ B. Altman, Teri E. Klein, Howard L. McLeod, 2010, Pharmacogenetics and genomics.

Inﬂammation, Growth Factors, and Pulmonary Vascular Remodeling

M. Maitland, M. Humbert, J. Barberà, 2016 .

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Soma Das, Federico Innocenti, Michael L Maitland, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway.

M. Maitland, M. Ratain, W. Stadler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors

M. Maitland, T. Karrison, K. Wroblewski, 2014, Journal of clinical pharmacology.

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

L. Schwartz, J. Meyerhardt, M. Maitland, 2019, Journal of Clinical Oncology.

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Lynne Wagner, Dennis P. West, Ethan Basch, 2010, Supportive Care in Cancer.

Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension

Yusuke Nakamura, E. Gamazon, A. Konkashbaev, 2019, Pharmacogenetics and genomics.

Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.

Yusuke Nakamura, M. Maitland, M. Dolan, 2013, Pharmacogenomics.

Selective adipocyte loss of Angiopoietin-2 prompts female-specific obesity and metabolic syndrome

M. Maitland, B. Mitchell, K. Ryan, 2022, Molecular metabolism.

Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.

M. Maitland, A. Tolcher, S. Ou, 2014 .

Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response.

G. Rosner, M. Maitland, M. Ratain, 2010 .

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.

M. Maitland, D. Gandara, S. Ramalingam, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients

M. Maitland, R. Schilsky, M. Ratain, 2013, Clinical Cancer Research.

Identifying Novel Drug Targets by iDTPnd: A Case Study of Kinase Inhibitors

Hammad Naveed, M. Maitland, Xin Gao, 2021, Genom. Proteom. Bioinform..

Identifying Novel Targets by using Drug-binding Site Signature: A Case Study of Kinase Inhibitors

Hammad Naveed, Thomas Schubert, Corinna Reglin, 2019, bioRxiv.

Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer.

M. Maitland, S. Rich, S. Archer, 2008, American journal of physiology. Heart and circulatory physiology.

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.

M. Maitland, C. Kyratsous, D. Lebwohl, 2021, The New England journal of medicine.

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors

M. Maitland, J. Bendell, G. Senaldi, 2017, Investigational New Drugs.

Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth

M. Maitland, Qiwei Yang, S. Cohn, 2012, Pediatric blood & cancer.

388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors

M. Maitland, M. Ratain, Jennifer A. Smith, 2010 .

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

M. Maitland, M. Ratain, K. Vasisht, 2006, Trends in pharmacological sciences.

Comparative genomics analysis of human sequence variation in the UGT1A gene cluster

David B. Witonsky, B. Roe, M. Maitland, 2006, The Pharmacogenomics Journal.

Interpreting disparate responses to cancer therapy: the role of human population genetics.

Michael L Maitland, Mark J Ratain, M. Maitland, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.

L. Schwartz, Binsheng Zhao, M. Maitland, 2021, European journal of cancer.

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation

L. Schwartz, Binsheng Zhao, M. Maitland, 2020, Clinical Cancer Research.

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

L. Schwartz, Binsheng Zhao, M. Maitland, 2018, JCO clinical cancer informatics.

Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies

M. Maitland, M. Ratain, G. Bakris, 2014, Clinical pharmacology and therapeutics.

Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity

M. Maitland, Rajesh Gupta, 2011, Current hypertension reports.

Point RECIST : No Longer the Sharpest Tool in the Oncology

M. Maitland, M. Ratain, M. Sharma, 2012 .

PharmGKB summary: sorafenib pathways

R. Altman, L. Gong, T. Klein, 2017, Pharmacogenetics and genomics.

Interpreting P values in pharmacogenetic studies: a call for process and perspective.

M. Maitland, M. Ratain, N. Cox, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammation, growth factors, and pulmonary vascular remodeling.

M. Maitland, M. Humbert, J. Barberà, 2009, Journal of the American College of Cardiology.

Personalized treatment of lung cancer.

M. Maitland, R. Salgia, T. Hensing, 2011, Seminars in oncology.

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

M. Maitland, M. Ratain, P. O’Donnell, 2015, Clinical Cancer Research.

Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors

M. Maitland, K. Snider, K. L. Snider, 2009, Targeted Oncology.

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

M. Maitland, M. Ratain, J. Ramírez, 2011, Clinical Cancer Research.

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

D. Xuan, M. Maitland, A. Tolcher, 2021, Clinical Cancer Research.

Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial

L. Schwartz, Binsheng Zhao, M. Maitland, 2020, European Radiology.

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

M. Maitland, P. LoRusso, G. Abou-Alfa, 2017, Cancer Chemotherapy and Pharmacology.

A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors

M. Maitland, R. Schilsky, M. Ratain, 2008 .

Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

M. Maitland, M. Ratain, H. Black, 2009, Clinical Cancer Research.

Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology

Michael L Maitland, Mark J Ratain, M. Maitland, 2010, Clinical Cancer Research.

PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

D. Xuan, M. Maitland, A. Tolcher, 2018 .

Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets

Michael L Maitland, Mark J Ratain, M. Maitland, 2006, Annals of Internal Medicine.

Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

M. Maitland, M. Ratain, Y. Lussier, 2008, Physiological genomics.

Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.

M. Maitland, R. S. Huang, A. Loboda, 2015, Journal of the National Cancer Institute.

Bayesian inference for longitudinal data with non-parametric treatment effects.

P. Müller, G. Rosner, F. Quintana, 2014, Biostatistics.

RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.

Michael L Maitland, Mark J Ratain, M. Maitland, 2012, Cancer research.

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

M. Maitland, G. Bakris, H. Black, 2010, Journal of the National Cancer Institute.

Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer.

R. Wilcox, M. Maitland, P. Caligiuri, 2006, Lung Cancer.

Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

M. Maitland, M. Ratain, R. Bies, 2012, Clinical Cancer Research.

Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration

M. Maitland, M. Gopalakrishnan, Erik Dvergsten, 2023, CPT: pharmacometrics & systems pharmacology.

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.

D. Xuan, M. Maitland, A. Tolcher, 2018 .

Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib

J. O’Connell, Chun-Fang Xu, L. Cardon, 2014, Clinical Cancer Research.

Estimation of renal cell carcinoma treatment effects from disease progression modeling

M. Maitland, M. Ratain, R. Bies, 2012, Clinical pharmacology and therapeutics.

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.

M. Maitland, R. Schilsky, C. Drescher, 2023, JCO precision oncology.

Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC)

M. Maitland, R. Govindan, R. Salgia, 2008 .

A genotype-directed phase I study of irinotecan in advanced cancer patients

M. Maitland, M. Ratain, Soma Das, 2007 .

Models of Excellence: Improving Oncology Drug Development

M. Maitland, M. Ratain, M. Sharma, 2012, Clinical pharmacology and therapeutics.

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study

Binsheng Zhao, Sanja Karovic, Michael L Maitland, 2018, Cancer Chemotherapy and Pharmacology.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors

M. Maitland, M. Ratain, M. Bissonnette, 2018, Cancer Chemotherapy and Pharmacology.

A Serial NT-proBNP Model to Improve Prognostication in Patients with Pulmonary Arterial Hypertension

M. Maitland, M. Gomberg-Maitland, C. Glassner, 2017 .

Time to tumor growth: a model end point and new metric system for oncology clinical trials.

L. Schwartz, M. Maitland, M. Ratain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)

D. Xuan, M. Maitland, A. Tolcher, 2016 .

Cardiovascular toxicity of new agents.

M. Maitland, 2008, Clinical advances in hematology & oncology : H&O.

PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.

Meng Li, M. Maitland, J. Berlin, 2021 .

A time to keep and a time to cast away categories of tumor response.

M. Maitland, R. Bies, J. Barrett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis

Michael L Maitland, M. Maitland, 2010, Clinical Cancer Research.

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

M. Maitland, D. Carbone, C. Chung, 2014, BMC Cancer.

Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863).

M. Maitland, D. Gandara, S. Ramalingam, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammation, growth factors, and pulmonary vascular remodeling.

M. Maitland, M. Humbert, J. Barberà, 2009, Journal of the American College of Cardiology.

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling

M. Maitland, M. Ratain, E. Vokes, 2016, Clinical and translational science.

Clinical Trials Toolbox RECIST : No Longer the Sharpest Tool in the Oncology

M. Maitland, M. Ratain, M. Sharma, 2012 .

Clinical trials in the era of personalized oncology

M. Maitland, R. Schilsky, 2011, CA: a cancer journal for clinicians.

Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data

Yong Huang, Yves A. Lussier, Jianrong Li, 2010, J. Biomed. Informatics.

Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis

M. Maitland, 2010, Clinical Cancer Research.

Ccr Translations Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis Clinical Cancer Research

M. Maitland, 2022 .